Table II.
Unadjusted hazard ratio and 95% confidence intervals for melanoma-specific survival of different racial/ethnicity groups compared with non-Hispanic whites in the Surveillance, Epidemiology, and End Results cohort and across 3 diagnostic time periods for different stages for cutaneous melanoma
| <2000 |
2000–2009 |
≥2010 |
||||
|---|---|---|---|---|---|---|
| Race | HR (95% CI) for MSS | HR (95% CI) for MSS | P for interaction | HR (95% CI) for MSS | P for interaction | |
| Localized stage* | ||||||
| Hispanic | 0.93 (0.79–1.09) | 1.24 (1.08–1.43) | .007 | 1.35 (1.06–1.72) | .012 | |
| NHB | 1.62 (1.22–2.15) | 2.26 (1.70–3.02) | .10 | 4.29 (2.84–6.47) | <.001 | |
| NHAPI | 1.18 (0.89–1.57) | 1.47 (1.10–1.96) | .29 | 2.21 (1.42–3.43) | .020 | |
| NHAIAN | 0.82 (0.44–1.53) | 1.02 (0.58–1.80) | .61 | 1.98 (0.94–4.15) | .076 | |
| Regional stage* | ||||||
| Hispanic | 0.98 (0.81–1.18) | 1.24 (1.10–1.40) | .042 | 1.46 (1.22–1.75) | .003 | |
| NHB | 1.72 (1.30–2.27) | 1.48 (1.18–1.84) | .41 | 1.80 (1.28–2.52) | .84 | |
| NHAPI | 1.20 (0.90–1.59) | 1.31 (1.06–1.62) | .61 | 1.24 (0.82–1.88) | .88 | |
| NHAIAN | 2.25 (1.24–4.07) | 1.15 (0.72–1.83) | .080 | 2.72 (1.57–4.69) | .65 | |
| Distant stage* | ||||||
| Hispanic | 0.80 (0.64–1.00) | 1.01 (0.87–1.17) | .088 | 1.14 (0.96–1.35) | .014 | |
| NHB | 1.18 (0.89–1.56) | 0.78 (0.60–1.00) | .032 | 0.96 (0.70–1.32) | .34 | |
| NHAPI | 1.19 (0.87–1.63) | 1.02 (0.80–1.30) | .45 | 1.69 (1.28–2.25) | .10 | |
| NHAIAN | 1.51 (0.72–3.16) | 0.73 (0.35–1.54) | .18 | 0.82 (0.39–1.71) | .25 | |
| All stages* | ||||||
| Hispanic | 1.13 (1.02–1.25) | 1.61 (1.49–1.73) | <.001 | 1.96 (1.76–2.17) | <.001 | |
| NHB | 2.32 (1.99–2.72) | 2.88 (2.51–3.31) | .044 | 3.85 (3.16–4.68) | <.001 | |
| NHAPI | 1.77 (1.51–2.07) | 2.23 (1.95–2.55) | .029 | 2.76 (2.27–3.36) | .001 | |
| NHAIAN | 1.30 (0.91–1.86) | 1.34 (0.99–1.81) | .89 | 2.09 (1.45–3.01) | .067 | |
CI, Confidence interval; HR, hazard ratio; MSS, melanoma-specific survival; NHAIAN, non-Hispanic American Indian/Alaska Native; NHAPI, non-Hispanic Asian or Pacific Islander; NHB, non-Hispanic black; NHW, non-Hispanic white.
For each of the 4 models (localized stage, regional stage, distant stage, and all stages), the unadjusted HRs for MSS and P values were calculated from Cox proportional hazard models with race, year of diagnosis, and the interaction terms. P values in 2000–2009 showed significance comparing the HRs to NHWs for melanomas diagnosed in 2000–2009 and those for melanomas diagnosed <2000. P values in ≥2010 showed significance comparing the HRs to NHWs for melanomas diagnosed in ≥2010 and those for melanomas diagnosed before 2000.